Login / Signup

Clinical Features and Outcome of Multidrug-Resistant Osteoarticular Tuberculosis: A 12-Year Case Series from France.

Isabelle BonnetElie HaddadLorenzo GuglielmettiPascale BemerLouis BernardAnne BourgoinRachel BraultGaud CathoEric CaumesLélia EscautEric FourniolsMathilde Fréchet-JachymAlice GaudartHélène GuillotBarthélémy Lafon-DesmursJean-Philippe LanoixPhilippe LanotteAdrien LemaignenBénédicte LemaireNadine LemaitreChristophe MichauPhilippe MorandFaiza MougariDhiba Marigot-OuttandySolène Patrat-DelonThomas PerpointCaroline PiauValérie PourcherVirginie ZarroukValérie ZellerNicolas VezirisStéphane JauréguiberryAlexandra Aubrynull null
Published in: Microorganisms (2022)
The optimal treatment for osteoarticular infection due to multidrug-resistant tuberculosis strains (MDR-OATB) remains unclear. This study aims to evaluate the diagnosis, management and outcome of MDR-OATB in France. We present a case series of MDR-OATB patients reviewed at the French National Reference Center for Mycobacteria between 2007 and 2018. Medical history and clinical, microbiological, treatment and outcome data were collected. Twenty-three MDR-OATB cases were reported, representing 3% of all concurrent MDR-TB cases in France. Overall, 17 were male, and the median age was 32 years. Six patients were previously treated for TB, including four with first-line drugs. The most frequently affected site was the spine ( n = 16). Bone and joint surgery were required in 12 patients. Twenty-one patients (91%) successfully completed the treatment with a regimen containing a mean of four drugs (range, 2-6) for a mean duration of 20 months (range, 13-27). Overall, high rates of treatment success were achieved following WHO MDR-TB treatment guidelines and individualized patient management recommendations by the French National TB Consilium. However, the optimal combination of drugs, duration of treatment and role of surgery in the management of MDR-OATB remains to be determined.
Keyphrases